We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes
News

Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes

Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes
News

Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmacokinetics, Metabolism and Toxicity of Carbon Nanotubes for Biomedical Purposes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abstract

Carbon nanotubes (CNTs) have attracted great interest of the nano community and beyond. However, the biomedical applications of CNTs arouse serious concerns for their unknown in vivo consequence, in which the information of pharmacokinetics, metabolism and toxicity of CNTs is essential. In this review, we summarize the updated data of CNTs from the biomedical view. The information shows that surface chemistry is crucial in regulating the in vivo behaviors of CNTs. Among the functionalization methods, PEGylation is the most efficient one to improve the pharmacokinetics and biocompatibility of CNTs. The guiding effects of the pharmacokinetics, metabolism and toxicity information on the biomedical applications of CNTs are discussed.

This article is published online in Theranostics and is free to access.

Advertisement